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Methotrexate (MTX) is the most commonly used disease modifying anti rheumatic drug 
(DMARD) in the management of juvenile idiopathic arthritis (JIA). Gastrointestinal (GI) side effects 
include anticipatory, associative and post MTX nausea and vomiting (N&V) and using patient and 
parent reported data, are seen in at least 50% of patients taking MTX for JIA [1,2] 
These side effects often limit the use of MTX, have a significant impact on quality of life [2, 3] and 
can be a reason to escalate to second line treatment with a biologic agent, which has significant 
health economic implications. 
In UK paediatric rheumatology practice, variable strategies are used to prevent and manage MTX related 
N&V. In contrast to evidence-based guidelines available for emetogenic drugs in Paediatric 
oncology [4], no completed research studies or national guidelines on the use of antiemetics or 
other strategies to prevent and manage MTX-related N&V in JIA have been published. A PubMED 
search for evidence on the prevention and management of nausea and vomiting in non oncological 
use of methotrexate was performed and is presented in Supplementary information Table 1. This 
showed that evidence for the use of antiemetics or other strategies in conditions similarly treated 
with MTX in either adults or children, such as rheumatoid arthritis or Crohn disease, is very limited 
[5-8] 
We aimed to identify the strategies currently in use amongst prescribing members of the British 
Society of Paediatric and Adolescent Rheumatology (BSPAR) for the prevention and treatment of 
MTX related N&V, with a view to informing future prospective studies. BSPAR is a national 
organisation whose members are practicing doctors, nurses, allied health professionals and 
researchers within Paediatric Rheumatology from across the UK. 
 
An online survey using Survey Monkey web based software was devised and an invitation with weblink 
was circulated to the entire BSPAR membership, currently including an estimated number of 136 
prescribers of MTX for JIA. A subsequent reminder was sent out 2 months later. A summary of the 
main questions asked and results of responses is shown in Supplementary Table S1, available at 
Rheumatology online. 
Eighty-four respondents completed the survey including 29 of 45 practising UK Paediatric 
Rheumatology consultants, 22 Paediatricians and 10 Consultant Adult Rheumatologists with an 
interest in Paediatric Rheumatology, and 21 other prescribing practitioners with a 62% overall 
response rate. 
Over half of all respondents estimated that N&V developed in >25% of JIA patients on MTX and 63% 
of respondents estimated that greater than 10% of patients were changed to biologic agents 
primarily due to gastrointestinal side effects. 
On starting methotrexate for the treatment of arthritis in JIA, only 21% of respondents always or 
often (defined as greater than 50% of the time) start an antiemetic. Ondansetron was the first 
choice of antiemetic for 88% of respondents. Factors increasing the likelihood of prescribing 
antiemetic drugs were a child prone to nausea and vomiting and parental anxiety or request. 
In relation to concomitant folic acid, 67% of respondents always or often start folic acid. No other 
strategy to prevent side effects was routinely used. 
The three most common strategies to deal with anticipatory N&V related to MTX, combining first 
and second choices (when not routine on starting MTX) were: starting an antiemetic (70%), a team 
member teaching behavioural techniques (49%) and changing the route of administration of MTX 
(38%). Clinical psychology and adding folic acid were used with a similar frequency (37%). 
The most frequently used management strategies for post-MTX N&V, combining first and second 
choices (when these were not routine on starting MTX) were: starting an antiemetic (100%), starting 
folic acid (74%) and changing the route of administration of MTX (57%). 
Clinical psychology intervention was used within the first 3 strategies by 73% and 35% of 
respondents for anticipatory N&V and post MTX N&V respectively. However access to care may have 
limited the use of this strategy with 22% of respondents reporting no access at all to clinical 
psychology services and only 30% of respondents benefitting from a dedicated service. 
Changing to a biologic was considered by 57% and 54% of respondents, as third choice or lower 
strategy for managing anticipatory or post MTX- related nausea. However only 5 % of respondents 
stated they would not consider this strategy for MTX related side effects. 
In summary MTX-related N&V is recognised as a common problem amongst prescribers of MTX for 
JIA potentially significantly contributing to the need to escalate treatment to biologic drugs. 
Preventative approaches and in particular antiemetic prescribing on starting MTX to prevent 
anticipatory and post-MTX N&V, are not supported by evidence of efficacy and are inconsistently 
used. Variable strategies are used to manage side effects, including the use of anti-emetics, folic acid 
and psychological interventions. 
 
This survey identified the most commonly used strategies used by a significant proportion of UK 
MTX-prescribers for JIA. A study to compare these strategies, including the preventative use of 
antiemetics, is urgently needed and strongly supported by the MCRN/Arthritis Research UK Clinical 
Study Group including the consumer representatives. 
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Supplementary Information 
Table 1 Summary of PubMed searches for studies into the prevention and 
management of Methotrexate related nausea and vomiting (non-oncological 
use). 
 
Search Terms Number 
of papers 
returned 
Number 
of 
relevant 
papers 
 
References Summary of findings 
Methotrexate 123 2 Blanco R, Gonzalez-Gay MA, Open label interventional 
AND Antiemetic 
AND Arthritis 
Garcia-Porrua C, et al. 
Ondansetron prevents 
refractory and severe 
methotrexate-induced nausea 
in rheumatoid arthritis. Br J 
Rheumatol. 1998; 37:590–591 
[6]. 
 
 
 
Devlin J, Wagstaff K, Arthur V, 
et al. Granisetron (Kytril) 
suppresses methotrexate 
induced nausea and vomiting 
among patients with 
inflammatory arthritis and is 
superior to prochlorperazine 
(Stemetil). Rheumatology. 
1999;38: 280–82 [7]. 
 
study. 
9 adult patients with RA 
and nausea refractory to 
metoclopramide and 
switch to IM route. 
All patients had reduction 
in nausea duration and 
intensity with ondansetron. 
 
 
Randomised single blinded 
interventional study. 
Comparison of granisetron 
vs prochlorperizine in 
13 adult patients with RA 
or Psoriatic Arthritis 
All patients randomised to 
granisetron reported 
significantly improved 
symptoms compared to 
those randomised to 
prochlorperizine. 
Methotrexate 
AND 
Prevention 
AND Nausea 
60 2 Kempinska A, Benchimol 
EI, Mack A, et al. Short-course 
ondansetron for the 
prevention 
of methotrexate-induced 
nausea in children with Crohn 
disease. J Pediatr 
Gastroenterol Nutr. 2011 
Oct;53(4):389-93 [8]. 
 
 
 
Shea B, Swinden MV, 
Tanjong 
Ghogomu E, et al. 
Folic acid and folinic acid for 
reducing side effects in 
patients 
receiving methotrexate 
for rheumatoid arthritis. 
Cochrane Databas 
Retrospective case control 
study. 
64 children with Crohn 
disease on methotrexate. 
4 of 50 patients given 
ondansatron on starting 
methotrexate developed 
nausea vs 6/10 patients 
not prescribed 
ondansetron. 
 
Meta-analysis of 6 RCTs of 
low dose folic or folinic 
acid supplementation with 
MTX including 624 patients 
with RA. 
26% relative risk reduction 
of the incidence of GI side 
effects. 
Methotrexate 
AND Treatment 
AND Nausea 
756 2 
(excluding 
previously 
reported 
papers) 
van der Meer A, Wulffraat NM, 
Prakken BJ, Gijsbers B, 
Rademaker CM, Sinnema G. 
Psychological side effects of 
MTX treatment in juvenile 
idiopathic arthritis: a pilot 
study. 
Clin Exp Rheumatol. 2007 
May-Jun;25(3):480-5 [10]. 
 
Alsufyani K, Ortiz-Alvarez O, 
Cabral DA, Tucker LB, Petty 
RE, Malleson PN. 
The role of subcutaneous 
administration of methotrexate 
in children with juvenile 
idiopathic arthritis who have 
failed oral methotrexate. J 
Rheumatol. 2004 
Jan;31(1):179-82 (not 
Case series of 29 patients 
with JIA on MTX. 
10 were referred to 
psychology for MTX side 
effects with improvement 
in symptoms. 
 
 
 
 
Retrospective case series 
of 61 children with JIA, 31 
of whom switched to SC 
MTX for oral MTX 
inefficacy or side effects. 
9 of 11 children with 
nausea reported 
improvement after change 
of route. 
reference in the main paper). 
 
Abstracts were reviewed by the main author and prospective and retrospective observational and 
interventional studies regarding the use of antiemetics and other strategies to prevent nausea and 
vomiting in non-oncological regimens using methotrexate were included. Single case reports were 
disregarded. 
 
Several papers related to the use of folic and folinic acid have been omitted due to their inclusion in 
the Cochrane systematic review on this subject. 
